CN113318002B - 消炎祛痘组合物及化妆品 - Google Patents
消炎祛痘组合物及化妆品 Download PDFInfo
- Publication number
- CN113318002B CN113318002B CN202110657506.XA CN202110657506A CN113318002B CN 113318002 B CN113318002 B CN 113318002B CN 202110657506 A CN202110657506 A CN 202110657506A CN 113318002 B CN113318002 B CN 113318002B
- Authority
- CN
- China
- Prior art keywords
- parts
- acne
- inflammatory
- cosmetic
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 78
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 72
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 35
- 239000002537 cosmetic Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title abstract description 70
- 241000123887 Pulsatilla chinensis Species 0.000 claims abstract description 20
- 208000020154 Acnes Diseases 0.000 claims abstract description 18
- BMWPBKOFJSHJAW-UHFFFAOYSA-N Saponin B Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O BMWPBKOFJSHJAW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930182490 saponin Natural products 0.000 claims abstract description 16
- 150000007949 saponins Chemical class 0.000 claims abstract description 16
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 241000186427 Cutibacterium acnes Species 0.000 claims description 22
- 108090001005 Interleukin-6 Proteins 0.000 claims description 16
- 102000043136 MAP kinase family Human genes 0.000 claims description 16
- 108091054455 MAP kinase family Proteins 0.000 claims description 16
- 108090001007 Interleukin-8 Proteins 0.000 claims description 15
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000008223 sterile water Substances 0.000 claims description 14
- 230000001815 facial effect Effects 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 12
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 9
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 8
- 229940055019 propionibacterium acne Drugs 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 36
- 206010061218 Inflammation Diseases 0.000 abstract description 14
- 230000004054 inflammatory process Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 13
- 208000026935 allergic disease Diseases 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 230000007815 allergy Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 206010067482 No adverse event Diseases 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 26
- 229930184121 pulsatilla saponin Natural products 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 18
- 235000017709 saponins Nutrition 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 241000206469 Pulsatilla Species 0.000 description 12
- 230000019491 signal transduction Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000028709 inflammatory response Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- -1 pH regulators Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003255 anti-acne Effects 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000003467 diminishing effect Effects 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 108010014632 NF-kappa B kinase Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002454 frontal bone Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- BOCBOJPUWMTAJB-UHFFFAOYSA-N (2-butylphenyl) 2-hydroxybenzoate Chemical compound CCCCC1=CC=CC=C1OC(=O)C1=CC=CC=C1O BOCBOJPUWMTAJB-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- HPVKSGLGOKNQON-UHFFFAOYSA-N 3-O-(beta-D-galactopyranosyl-(1->3)-beta-D-glucopyranosyl)serjanic acid 28-O-beta-D-glucopyranoside Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O HPVKSGLGOKNQON-UHFFFAOYSA-N 0.000 description 1
- BTXXTMOWISPQSJ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-one Chemical compound CC(=O)CC(F)(F)F BTXXTMOWISPQSJ-UHFFFAOYSA-N 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- BQACOLQNOUYJCE-FYZZASKESA-N Abietic acid Natural products CC(C)C1=CC2=CC[C@]3(C)[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1 BQACOLQNOUYJCE-FYZZASKESA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 102000008379 I-kappa B Proteins Human genes 0.000 description 1
- 108010021699 I-kappa B Proteins Proteins 0.000 description 1
- 230000004950 I-kappaB phosphorylation Effects 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010084331 Omiganan Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- OUHBKBTZUPLIIA-OTEDBJMHSA-N [(2s,3r,4s,5s,6r)-6-[[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (1r,3as,5ar,5br,7ar,8r,9s,11ar,11br,13ar,13br)-9-[(2s,3r,4s,5s)-4,5-dihydroxy- Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@H]([C@@H](CC3)C(C)=C)[C@@H]3[C@@]([C@]5(C)CC[C@H]6[C@](C)(CO)[C@@H](O[C@H]7[C@@H]([C@@H](O)[C@@H](O)CO7)O[C@H]7[C@@H]([C@H](O)[C@@H](O)[C@H](C)O7)O)CC[C@]6(C)[C@H]5CC3)(C)CC4)O2)O)[C@H](O)[C@H]1O OUHBKBTZUPLIIA-OTEDBJMHSA-N 0.000 description 1
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 1
- SVRHJWALMLOXMI-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 SVRHJWALMLOXMI-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- CMDKPGRTAQVGFQ-RMKNXTFCSA-N cinoxate Chemical compound CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1 CMDKPGRTAQVGFQ-RMKNXTFCSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- MCPKSFINULVDNX-UHFFFAOYSA-N drometrizole Chemical compound CC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 MCPKSFINULVDNX-UHFFFAOYSA-N 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- XOEUGELJHSUYGP-UHFFFAOYSA-N octyl 4-aminobenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=C(N)C=C1 XOEUGELJHSUYGP-UHFFFAOYSA-N 0.000 description 1
- MVPAMLBUDIFYGK-BHDRXCTLSA-N omiganan Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(N)=O)=CNC2=C1 MVPAMLBUDIFYGK-BHDRXCTLSA-N 0.000 description 1
- 229950008583 omiganan Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- VKYWCHMXHQTCJQ-UHFFFAOYSA-N pentyl 4-aminobenzoate Chemical compound CCCCCOC(=O)C1=CC=C(N)C=C1 VKYWCHMXHQTCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XATKDVHSLQMHSY-RMKNXTFCSA-N propan-2-yl (e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC=C(\C=C\C(=O)OC(C)C)C=C1 XATKDVHSLQMHSY-RMKNXTFCSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种消炎祛痘组合物,包括以下重量份数的原料:白头翁皂苷B4 3‑6份,白头翁皂苷B5 3‑4份,白头翁皂苷BD 1‑3份,白头翁皂苷B3 1‑2份,白头翁皂苷B7 1‑2份。本发明还公开了所述的组合物在化妆品中的应用。本发明还公开了一种化妆品。本发明还公开了一种消炎祛痘面膜。本发明能够去除痤疮、粉刺、消炎、祛痘、修复痘印,总体治疗效果好,且本品为中药提取物无过敏等不良反应,在治疗痤疮的同时,可以保护皮肤不收化学成分的损害,治疗全面。
Description
技术领域
本发明涉及化妆品。更具体地说,本发明涉及一种消炎祛痘组合物及化妆品。
背景技术
皮肤是人体最大的器官,也是应对外界的第一道防护屏障。今年来,随着人们生活质 量的提升,大家对皮肤健康也投入了更多的关注。常见的皮肤问题主要有痤疮炎症、肤色 暗沉、皮肤敏感等。痤疮炎症是一种常见的皮肤问题,约80%的人都曾收到痤疮的影响。痤疮发病率高举不下的主要原因有:遗传因素、环境污染、饮食习惯、生活压力和激素分 泌失调等。痤疮的发病机制主要有:皮脂过度溢出、毛囊角化异常、皮肤微生物组失衡以及痤疮炎症等。目前,国际上使用“三度四级分类法”,根据痤疮的严重程度分为轻度(I 级痤疮)、中度(II级和III级痤疮)和重度(IV级痤疮)。痤疮会引起脓疱、丘疹和囊肿 等症状,如果护理不当,痤疮病程可能由短期几个月延长至几年,并在皮肤上留下瘢痕, 进而影响患者的正常容貌。同时,人们对痤疮的偏见会导致患者自卑、抑郁和社交障碍等心理问题,从而影响患者的正常生活,降低生活质量和幸福感。
目前治疗痤疮主要通过口服或外用抗生素或抗炎药物来杀死痤疮相关细菌,抑制炎症 反应的发生,进而抑制痤疮的进一步发展,起到防止痤疮的作用。最常见的药物为四环素、 克林霉素、过氧化苯甲酰、硫磺、盐酸奥米茄南和壬二酸等。但以上药物在使用中发现,抗生素可能会打破皮肤正常微生物的平衡,从而引起皮疹和过敏等副作用,且容易产生耐 药性,带来不良影响,因此今年来,抗生素添加剂逐渐不再用作祛痘产品。而硫磺、过氧化苯甲酰和壬二酸等药物虽然已使用多年,但实际使用中发现有效性不高、且刺激性较大,易产生皮肤干燥和剥脱性皮炎等副作用。因此,人们对上述物质的使用态度也日趋谨慎。随着科技的不断发展,人们开始尝试新的物理疗法防治痤疮。红蓝光照射能够部分改变细 胞结构,灭活细菌;同时,促进细胞内胶原蛋白生成,但成本高,在实际应用中推广率也 不高。因此,开发疗效好、安全性高和物美价廉的新型抗痤疮产品迫在眉睫。
近年来天然植物收到的关注不断增多,天然植物的有效成分是治疗及预防各类疾病的 主要活性物质,因此,深入研究并开发植物的有效成分是目前研究的热点。
发明内容
本发明的一个目的是解决至少上述问题,并提供至少后面将说明的优点。
本发明还有一个目的是提供一种消炎祛痘组合物及化妆品,其能够去除痤疮、粉刺、 消炎、祛痘、修复痘印,总体治疗效果好,且本品为中药提取物无过敏等不良反应,在治疗痤疮的同时,可以保护皮肤不收化学成分的损害,治疗全面。
为了实现根据本发明的这些目的和其它优点,提供了一种消炎祛痘组合物,包括以下 重量份数的原料:白头翁皂苷B4 3-6份,白头翁皂苷B5 3-4份,白头翁皂苷BD 1-3份,白头翁皂苷B3 1-2份,白头翁皂苷B7 1-2份。
优选的是,所述组合物溶解于无菌水,所述组合物与无菌水的重量比为1-40μg/mL。
所述的组合物在化妆品中的应用。
优选的是,所述化妆品为洁面乳、护肤水、精华液、乳液、面霜、面膜液或眼霜。
优选的是,所述组合物抑制炎症因子IL-6、IL-1β和IL-8的释放。
优选的是,所述组合物抑制MAPK和NF-κB抗炎通路。
化妆品,有效成分为所述的组合物。
优选的是,所述组合物溶解于无菌水,所述组合物与无菌水的重量比为1-40μg/mL。
优选的是,所述化妆品为洁面乳、护肤水、精华液、乳液、面霜、面膜或眼霜。
消炎祛痘面贴膜,所述面贴膜浸有所述的组合物与无菌水混合制备成的面膜液。
本发明至少包括以下有益效果:
第一、本发明的组合物能够去除痤疮、粉刺、消炎、祛痘、修复痘印,总体治疗效果好,且本品为中药提取物无过敏等不良反应,在治疗痤疮的同时,可以保护皮肤不收化学成分的损害,治疗全面。其发挥消炎祛痘作用机制可能与抑制炎症因子IL-6、IL-1β和IL-8的释放,抑制MAPK和NF-κB抗炎通路相关。本发明为消炎祛痘化妆品防治痤疮提供了理论依据。
本发明的其它优点、目标和特征将部分通过下面的说明体现,部分还将通过对本发明 的研究和实践而为本领域的技术人员所理解。
附图说明
图1为组合物对P.acnes诱导THP-1细胞分泌IL-1β(A),IL-6(B)和IL-8(C)的 影响;
图2为组合物对P.acnes诱导THP-1细胞表达p-IKKα/β(A),p-IκB(B)和p-p65 mRNA(C)的影响;
图3为组合物对P.acnes诱导THP-1细胞表达p-JNK(A),p-ERK(B)和p-p38mRNA (C)的影响。
具体实施方式
下面结合附图对本发明做进一步的详细说明,以令本领域技术人员参照说明书文字能 够据以实施。
应当理解,本文所使用的诸如“具有”、“包含”以及“包括”术语并不配出一个或多个其它元件或其组合的存在或添加。
需要说明的是,下述实施方案中所述实验方法,如无特殊说明,均为常规方法,所述 试剂和材料,如无特殊说明,均可从商业途径获得。
消炎祛痘组合物,有效成分为白头翁皂苷B4、白头翁皂苷B5、白头翁皂苷BD、白 头翁皂苷B3、白头翁皂苷B7,以上配方的任一或组合均进行了试验验证,具有一定作用,组合的效果最佳,具体可以包括以下重量份数的原料:白头翁皂苷B4 3-6份,白头翁皂 苷B5 3-4份,白头翁皂苷BD 1-3份,白头翁皂苷B3 1-2份,白头翁皂苷B7 1-2份。使用 时,所述组合物溶解于无菌水,所述组合物与无菌水的重量比为1-40μg/mL。
白头翁皂苷B4的结构式如式(I)所示,
白头翁皂苷B5的结构式如式(II)所示,
白头翁皂苷BD的结构式如式(III)所示,
白头翁皂苷B3的结构式如式(IV)所示,
白头翁皂苷B7的结构式如式(V)所示,
为了将组合物制成在不同部位、按照不同手法都方便使用的化妆品形式时,例如制成 洁面乳、护肤水、精华液、乳液、面霜、面膜液或眼霜等不同形式时,上述组合物除了有效成分外,还可以包括将有效成分制成不同形式的辅料,例如油脂成分、保湿剂、润滑剂、紫外线吸收剂、pH调节剂、香料、血液循环促进剂、冷却剂、止汗剂、纯净水等。油脂 成分例如酯类油脂、烃油脂、硅油脂、氟油脂、动物油脂、植物油脂等。保湿剂例如水溶 性低分子保湿剂、脂溶性低分子保湿剂、水溶性高分子、脂溶性高分子等。润滑剂例如长 链酰基谷氨酸胆固醇酯、羟基硬脂酸胆固醇酯、12-羟基硬脂酸、硬脂酸、松香酸、羊毛脂脂肪酸胆固醇酯等。紫外线吸收剂例如对氨基苯甲酸、对氨基苯甲酸乙酯、对氨基苯甲 酸戊酯、对氨基苯甲酸辛酯、水杨酸乙二醇酯、水杨酸苯酯、水杨酸酯、水杨酸苄酯、水 杨酸丁基苯酯、水杨酸薄荷酯、肉桂酸苄酯、对甲氧基肉桂酸2-乙氧基乙酯、甲氧基肉桂 酸辛酯、二吡咯丙氧基丙氨酰-2-乙基己烷甘油酯、对甲氧基肉桂酸异丙酯、二异丙基/肉 桂酸二异丙酯酯混合物、尿刊酸、尿刊酸乙酯、羟基甲氧基二苯甲酮、羟基甲氧基二苯甲酮磺酸及其盐、二羟基甲氧基二苯甲酮、二羟基甲氧基二苯甲酮二磺酸钠、二羟基二苯甲 酮、四羟基二苯甲酮、4-叔丁基-4'-甲氧基二苯甲酰甲烷、2,4,6-三烷基-p-(碳-2'-乙基己基-1'- 氧)-1,3,5-三嗪、2-(2-羟基-5-甲基苯基)苯并三唑等。pH调节剂可例举柠檬酸、柠檬酸钠、 苹果酸、苹果酸钠、富马酸、富马酸钠、琥珀酸、琥珀酸钠、氢氧化钠、磷酸一氢钠等。
本发明的剂型为糊状物、霜或凝胶的情况下,可以使用动物纤维、植物纤维、蜡、石蜡、淀粉、黄芪胶、纤维素酶衍生物、聚乙二醇、硅胶、膨润土、二氧化硅、滑石粉或氧 化锌等作为载体成分。
本发明的剂型为粉末或喷雾的情况下,可以使用乳糖、滑石粉、二氧化硅、铝蛋白、硅酸钙或锦纶粉末作为载体成分,特别是剂型为喷雾的情况下,可以追加包含氟代烃、丙烷、桴炭或二甲基丁烷等推进剂。
本发明的剂型为溶液或乳状物的情况下,使用溶媒、溶媒化剂或乳化剂作为载体成分, 例如有水、乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苯甲醇、苯甲酸苄酯、丙二醇、1,3-丁二醇油、甘油脂族酯、聚乙二醇或失水山梨糖醇的脂肪酸酯。
本发明的剂型为悬浮液的情况下,可使用水、乙醇或丙二醇等的液态稀释剂、乙氧基 化异硬脂醇、聚氧乙烯山梨醇酯和聚氧乙烯脱水山梨糖醇酯等悬浮液、微晶纤维素、偏氢 氧化铝、膨润土、琼脂作为载体成分。
<实例1>
消炎祛痘组合物,包括以下重量份数的原料:白头翁皂苷B4 3份,白头翁皂苷B5 3份,白头翁皂苷BD 1份,白头翁皂苷B3 1份,白头翁皂苷B7 1份。
<实例2>
消炎祛痘组合物,包括以下重量份数的原料:白头翁皂苷B4 6份,白头翁皂苷B5 4份,白头翁皂苷BD 3份,白头翁皂苷B3 2份,白头翁皂苷B7 2份。
<实例3>
消炎祛痘组合物,包括以下重量份数的原料:白头翁皂苷B4 4份,白头翁皂苷B5 4份,白头翁皂苷BD 2份,白头翁皂苷B3 2份,白头翁皂苷B7 1份。
一、安全性能验证:
1.对用实例1-3制备的组合物的安全卫生性能检测,微生物结果如表1:
表1微生物结果
实例1 | 实例2 | 实例3 | |
菌落总数,CFU/g | ≤1000 | ≤1000 | ≤1000 |
霉菌和酵母菌总数,CFU/g | ≤100 | ≤100 | ≤100 |
耐热大肠杆菌/g | 未检出 | 未检出 | 未检出 |
金黄色葡萄球菌/g | 未检出 | 未检出 | 未检出 |
铜绿假单胞菌/g | 未检出 | 未检出 | 未检出 |
2.参照《化妆品安全技术规范2015》进行人体斑贴试验。
选择同时符合下列条件的志愿者作为受试对象:1)年龄在15~60周岁之间,男女均 可;2)无严重疾病,无免疫缺陷或自身免疫性疾病,受试部位未曾接受皮肤治疗、美容;3)无活动性过敏疾病;4)近两个月内受试部位未应用任何抗炎药物者;5)近一周使用 抗组胺药或近一个月未使用免疫抑制剂者;6)近一个月内未进行斑贴测试者。排除标准: 1)妊娠或哺乳期妇女;2)近两个月内受试部位应用过任何外用药物者;3)患有炎症性 皮肤病临床未愈者;4)在皮肤待测量区域由于瘢痕、色素、萎缩、鲜红斑痣或其它瑕疵而影响试验结果的判定者;5)近三个月内接受过可能影响皮肤弹性的面部美容手术或其 它美容方式者。中止及退出标准:在试验期间未按测试要求进行涂抹受试样品或未按要求 进行回访记录。24位志愿者签署志愿者知情同意书。受试区域为面部颧骨部位。每次测 试前,受试者统一清洁面部,并用无屑吸水干纸巾吸干。在符合标准的测试环境中静坐至少20min,不能喝水和饮料。受试者保持放松,面部暴露,避免触碰。左、右面部分为样 品涂抹侧和对照侧,确保在统计学上达到平衡,分别在左、右额骨部位确定测量区域,各 测量区域面积为3cm×3cm,分别持续24h和48h后观察皮肤状态。
试验结果表明,24和48h分别揭开斑贴,24位志愿者的左、右额骨部位对比来看,均未出现红斑、水肿、麻痒刺痛感。
二、药理学验证:
1.背景
痤疮丙酸杆菌的过度增殖和痤疮的发生及发展是紧密关联的。当痤疮丙酸杆菌侵袭皮肤毛囊时,痤疮丙酸杆菌表明的PAMP可被机体的免疫细胞如人单核细胞等通过Toll样受 体等识别,从而激活下游相关炎症信号通路,引起皮肤产生免疫应答来对抗痤疮丙酸杆菌 侵袭。
NF-κB(核因子激活的B细胞的κ-轻链增强)和MAPK(丝裂原活化蛋白激酶)信号 通路介导的炎症反应是宿主防御病原体的关键通路。NF-κB是炎症反应中关键的转录因子,具有信息传导作用。在未受刺激的细胞中,IκB蛋白与NF-κB亚基结合并将其隔离在细胞 质中。当细胞受到外界刺激引起IκB磷酸化依赖的蛋白酶体降解,释放NF-κB亚基,使 其从细胞质转移到细胞核。核导入的NF-κB亚单位与κB元件结合,启动炎症反应相关靶 基因的表达;同时,细胞的外刺激可影响MAPK中ERK、JNK和p38蛋白的磷酸化,进 而将细胞受侵染的信号转导到细胞核及其他相关细胞器,最终引发后续的炎症反应。在上 述免疫应答过程中,会产生炎性细胞因子IL-1β,IL-6,IL-8。
本申请进行消炎祛痘功效的研究,通过对IL-1β,IL-6和IL-8三种炎性细胞因子的转 录和对NF-κB及MAPK信号通路的抑制作用来研究消炎祛痘机制。结果显示组合物可显著抑制IL-1β,IL-6和IL-8分泌,抑制NF-κB及MAPK信号通路的激活,具有很好的消 炎祛痘潜力。
2.实验材料和方法
2.1细胞和细菌
人单核细胞THP-1细胞来自ATCC细胞库,痤疮丙酸杆菌P.acnes来自上海祥生物有限公司。
2.2药物及主要试剂
白头翁皂苷B4、白头翁皂苷B5、白头翁皂苷BD、白头翁皂苷B3、白头翁皂苷B7 由实验室提取分离制备。1640培养基、胎牛血清(FBS)和PBS购于Gibco,BCA蛋白 定量试剂盒和ELISA试剂盒,购于美国Thermo公司。
2.3主要仪器
恒温金属浴(BILL-10B,上海比郎仪器制造有限公司);电热鼓风干燥箱(101-1A,天津市泰特斯仪器有限公司);生物安全柜(BSC-1004IIA2,苏州安泰空气技术有限公司);CO2培养箱(371,美国Thermo公司);多功能微孔板检测仪(SYNERGYH1,美国伯腾 仪器有限公司);低温高速离心机(Centrifuge 5424R,德国Eppendrof公司);离心机(TD5Z,湖南凯达科学仪器有限公司);PCR仪(Applied Biosystems,美国Thermo公司);涡旋机 (QL-902,海门市其林贝尔仪器制造有限公司);医用冷藏冷冻箱(MPR-440F,松下冷链 有限公司);数显恒温水浴锅(HH-6,常州国华电器有限公司)。
2.4实验方法
2.4.1细胞培养
THP-1培养于含10%胎牛血清(FBS)的1640培养基中,置于37℃,5%CO2培养箱中。
2.4.2组合物对THP-1细胞中分泌IL-1β,IL-6和IL-8炎症因子的影响
THP-1细胞以1×105/mL的密度接种于24孔板过夜,用实例3制备的组合物溶于无菌 水得到的混合物(图1中简称白头翁皂苷)(5,10,20μg/mL)预处理细胞1h后,给予P.acnes菌体(4×107CFU/mL)刺激24h,收集上清,ELISA法测定上清液中IL-1β,IL-6 和IL-8的释放。
2.4.3 q-PCR法检测组合物对NF-κB,MAPK信号通路的影响
(1)THP-1细胞以5×105/mL的密度接种于6孔板过夜,用实例3制备的组合物溶 于无菌水得到的混合物(图2-3简称白头翁皂苷)(5,10,20μg/mL)预处理细胞1h后, 给予P.acnes菌体(4×107CFU/mL)刺激24h。从培养箱中取出6孔板,冰上弃掉培养基 后用2mL的PBS清洗2遍,将培养基洗干净;
(2)每孔中加入Trizol裂解液1mL,在冰上充分裂解5-10min后吹打混匀后将液 体转移到1.5mL离心管中;
(3)每管中加入氯仿溶液0.2mL,涡旋机涡旋使其充分萃取,冰上静置10min。 离心机4℃预冷,14000rpm,离心15min。离心完成后,管内液体分为三层,将上层液体 小心吸出,不要触碰到中层以及下层溶液,转移入新的RNase-free离心管中;
(4)每管加入0.5mL异丙醇混匀后置于冰上10min。静置完成后,4℃,14000rpm, 离心10min,在不碰触下层沉淀的前提下将上层液体弃掉;
(5)用无水乙醇以及DEPC水新鲜配置75%乙醇,每管加入1mL,充分洗涤RNA, 4℃,14000rpm,离心5min,弃掉上层液体,在室温下干燥RNA,直至RNA呈现无色 透明状;
(6)每管干燥的RNA中加入50-100μL DEPC水,充分溶解RNA后,吸取2μL 于超微量核酸分析仪中进行定量,其余RNA溶液保存于-80℃冰箱备用。
2.4.4逆转录
在RNase-free离心管管内加入1μg的模板RNA,并加入Oligo(dT)18primer 1μL,用DEPC水补充至12μL,再向管内按照表2加入试剂:
表2 cDNA合成体系
5×反应缓冲液 | 4μL |
RNA酶抑制剂(20U/μL) | 1μL |
10mM dNTP混合液 | 2μL |
RevertAid M-MuL V RT(200U/μL) | 1μL |
总体积 | 20μL |
试剂全部加完后,离心30s后使用Bio-rad T100 Thermal Cycler,42℃条件下孵育60 min;然后在70℃加热5min灭火逆转录酶以终止反应,然后取出PCR管置于冰上;
2.4.5实时定量PCR(real-time PCR)
引物序列如表3所示:
表3引物表
按照表3,在PCR管内配置反应体系,如表4所示:
表4反应体系
轻微震荡混匀反应体系,并离心1min以除去气泡。将PCR管置于PCR仪中,按照 表5所示进行扩增反应:
表5反应体系
Tem | Time | Cycle | |
Holding stage | 95 | 2min | 1 |
95 | 1min | ||
Cycling stage | 58 | 30s | 40 |
72 | 1min | ||
Melt curve stage | 65-95 | 2-5s | 1 |
2.5统计学分析
运用GraphPad Prism 6.0软件分析实验数据,均以mean±SD表示,进行单因素方差 分析(ANOVA)评价组间差异的显著性,具有统计学意义*P<0.05、**P<0.01、***P<0.001。
3.结果
3.1组合物对IL-1β,IL-6和IL-8的影响
如图1所示,P.acnes诱导THP-1细胞产生炎症反应,使胞外炎症因子IL-1β,IL-6和IL-8分泌量显著升高(##p<0.01),即证明模型建立成功。与模型组相比,使用不同浓度 的组合物(5,10,20μg/mL)进行孵育后,抑制了IL-1β,IL-6和IL-8炎症因子的释放, 且呈剂量依赖性。这说明组合物是浓度依赖地抑制胞外炎症因子的分泌。
3.2组合物对NF-κB信号通路的影响
当P.acnes诱导THP-1细胞时,下游的NF-κB信号通路被激活,从而由细胞质转移细胞核中并参与后续炎症反应。如图2所示,当P.acnes刺激THP-1细胞,磷酸化的NF-κB mRNA水平较空白对照组明显增加,提前用组合物处理的THP-1细胞后,磷酸化的NF-κB mRNA水平较P.acnes组减少,并且具有梯度依赖性。此外,P.acnes增加了p-IKKα/β,p-IκB 的mRNA水平,用组合物预处理的细胞,抑制了p-IKKα/β,p-IκB mRNA的水平。实验 结果说明,组合物可以有效地抑制NF-κB通路相关基因的mRNA的表达,通过抑制NF-κB 的活化起到抗炎作用。
3.3组合物对MAPK信号通路的影响
当P.acnes处理THP-1细胞时,会激活下游的MAPK信号通路并产生免疫炎症反应。因此本研究检测了组合物对P.acnes诱导THP-1细胞中MAPK信号通路的影响。
由图3可知,P.acnes可增加JNK、ERK和p38 mRNA磷酸化。当使用不同浓度组合 物(5,10,20μg/mL)进行孵育后,发现这些mRNA的磷酸化水平都有所下降,且呈剂 量依赖状态。这说明组合物皆可通过抑制MAPK信号通路来抑制P.acnes诱导的炎症反应。
4.结论
本研究主旨在于研究组合物在痤疮丙酸杆菌诱导的免疫应答的机制,以探究组合物的 消炎祛痘潜力。
(1)生理状态下,人体内有IL-1β,IL-6和IL-8水平较低,而病理状态下,人体内TNF-α、IL-6和IL-1β分泌大量增加促进炎症细胞的激活,并在体内形成“瀑布效应”,导 致炎症介质数量不断增加,进而引起组织细胞损伤。通过对IL-1β,IL-6和IL-8炎症因子 的检测,发现组合物是剂量依赖性地抑制炎症因子的表达和分泌。
(2)P.acnes刺激THP-1后,其下游的NF-κB,MAPK信号被激活,IL-1β,IL-6和 IL-8导致炎症因子的释放,继而引起炎症反应的发生。通过使用q-PCR法对NF-κB和 MAPK信号通路相关基因的mRNA水平的检测,发现组合物的通过NF-κB和MAPK信号 通路来抑制P.acnes诱导炎症反应。
本研究说明组合物是活性非常好的潜在的抗炎祛痘药,可能是通过抑制NF-κB,MAPK信号通路的激活,进而抑制下游炎症因子的表达而发挥抗炎作用。
三、消炎祛痘临床试验
1.面贴膜的制备
以消炎祛痘无纺布面贴膜为例,用实例3制备的组合物制备,将实例3制备的组合物 溶解于无菌水,所述组合物与无菌水的重量比为1-10μg/mL,加入表面活性剂、防腐剂、香精,混合均匀,脱气、过滤、冷却,形成面膜液,面贴膜浸有面膜液,折叠,用无菌铝 箔袋装袋,进行钴-60伽马射线照辐照灭菌,照射剂量6kgy,照射时间24h,即得。
2.面贴膜的使用
使用方法为:将面膜在洁面后敷在患者面部,每次20分钟,每周三次。本申请的除痘面膜对痤疮、青春痘和粉刺等,在其未化脓时,可以消肿。已成脓时可以排脓生肌。而 且具有去除印痕,恢复皮肤弹性,使痘印坑洼部位具有舒展平缓作用。自2020年4月至2021年4月,本产品经数百人试用,据反馈,从未发生皮肤被损害的事例。效果不明显 者仅有一人,其余均达到满意或较满意的效果。
3.面贴膜的典型例证:
(1)崔XX,男,27岁,脸上反复长痘长达5年,由于长时间面对电脑工作,经常 熬夜,饮食不规律,脸上容易起油污,反复长痘,并且经常用手抠,留下了许多痘印疤痕。 2020年4月初开始使用消炎祛痘无纺布面贴膜,两个月后痘痘消退。脸上毛孔变小,疤 痕有明显减退,并且脸上不再出油,不再反复长痘。
(2)赵XX,男,28岁,脸上长痘6年之久,反复了很长时间。由于吃辛辣食物或 海鲜,会发作比较厉害。2020年10月开始使用消炎祛痘无纺布面贴膜,一周后,脸上红肿痘痘开始消肿,一个月后明显好转很多,两个月后祛痘效果很明显,对红肿具有改善作 用。
(3)王XX,女,26岁,研究生,由于实验繁忙,压力较大,脸上长满了痘痘,使 用多种方法均无明显效果。2020年12月开始使用消炎祛痘无纺布面贴膜,一周后,脸上 痘痘开始变小,两周后小痘痘开始消退,痘印变淡,皮肤变得具有弹性。
(4)韩X,女,32岁,左脸颊长了黄豆大小的疥疮,开始发痛发胀,疥疮底部坚硬, 打了两天消炎针但没有消退,2021年2月使用消炎祛痘无纺布面贴膜后,第二天脓包变 软,不再发痛发胀,使用第七天,脓包消退。
(5)李XX,女,25岁,上初中时脸上就经常长疙瘩,也曾治疗过,但没有治好, 且花费很多治疗费用。2021年3月开始使用消炎祛痘无纺布面贴膜后,一周就见效了, 皮肤变的光滑,痘印变淡,并且不再反复长疙瘩,毛孔变小。
(6)何X,女,17岁,脸上长满了青春痘,用了多种药物治疗均无明显效果,2021 年4月开始使用消炎祛痘无纺布面贴膜,一周后脸上的痘痘开始由大变小,两周后痘痘基 本消退,对红肿具有改善,皮肤变的白细。
4.结论
综上所述,消炎祛痘无纺布面贴膜对去除痤疮、粉刺、消炎、祛痘、修复痘印的功效, 总体治疗效果好,且本品为中药提取物无过敏等不良反应,在治疗痤疮的同时,可以保护 皮肤不收化学成分的损害,治疗全面。白头翁皂苷具有消炎祛痘作用,白头翁皂苷组合物 制备的洁面乳、护肤水、精华液、乳液、面霜、面膜液或眼霜等不同形式的化妆品均具有相应的疗效。
这里说明的设备数量和处理规模是用来简化本发明的说明的。对本发明的应用、修改 和变化对本领域的技术人员来说是显而易见的。
尽管本发明的实施方案已公开如上,但其并不仅仅限于说明书和实施方式中所列运用, 它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地实现 另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下,本发明并不限于特定的细节和这里示出与描述的图例。
Claims (6)
1.消炎祛痘化妆品,其特征在于,包括以下重量份数的原料:白头翁皂苷B43-6份,白头翁皂苷B53-4份,白头翁皂苷BD 1-3份,白头翁皂苷B31-2份,白头翁皂苷B71-2份;
所述消炎祛痘指的是预防痤疮丙酸杆菌产生的痤疮。
2.如权利要求1所述的化妆品,其特征在于,所述化妆品溶解于无菌水,所述化妆品与无菌水的重量比为1-40μg/mL。
3.如权利要求1所述的化妆品,其特征在于,所述化妆品为洁面乳、护肤水、精华液、乳液、面霜、面膜液或眼霜。
4.如权利要求1所述的化妆品,其特征在于,所述化妆品抑制炎症因子IL-6、IL-1β和IL-8的释放。
5.如权利要求1所述的化妆品,其特征在于,所述化妆品抑制MAPK和NF-κB抗炎通路。
6.消炎祛痘面贴膜,其特征在于,所述面贴膜浸有权利要求2所述的化妆品与无菌水混合制备成的面膜液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110657506.XA CN113318002B (zh) | 2021-06-12 | 2021-06-12 | 消炎祛痘组合物及化妆品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110657506.XA CN113318002B (zh) | 2021-06-12 | 2021-06-12 | 消炎祛痘组合物及化妆品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113318002A CN113318002A (zh) | 2021-08-31 |
CN113318002B true CN113318002B (zh) | 2024-01-19 |
Family
ID=77420688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110657506.XA Active CN113318002B (zh) | 2021-06-12 | 2021-06-12 | 消炎祛痘组合物及化妆品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113318002B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114159453A (zh) * | 2021-12-24 | 2022-03-11 | 广西馨海药业科技有限公司 | 白头翁皂苷b4在制备治疗或预防银屑病的药物的用途 |
WO2023138280A1 (zh) * | 2022-01-18 | 2023-07-27 | 广西馨海药业科技有限公司 | 促进生发组合物、促进生发药物及应用 |
CN114469969B (zh) * | 2022-01-28 | 2022-09-27 | 中国中医科学院中药研究所 | 白头翁皂苷b5在制备皮肤护理品中的应用 |
CN114452292B (zh) * | 2022-01-28 | 2022-09-27 | 中国中医科学院中药研究所 | 白头翁皂苷b4在制备皮肤护理品中的应用 |
CN114712375B (zh) * | 2022-04-22 | 2023-11-03 | 苏州大学 | 一种羟基白桦酸化合物在制备皮肤病药物中的应用 |
CN114681474B (zh) * | 2022-05-10 | 2023-11-24 | 广西林洋药业有限公司 | 一种具有消肿止痒作用的组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108451964A (zh) * | 2018-07-02 | 2018-08-28 | 苏州大学 | 白头翁皂苷b5在制备抗炎症性肠病药物中的应用 |
CN111249289A (zh) * | 2020-02-14 | 2020-06-09 | 广西英路维特药物有限公司 | 一种消炎和/或抗过敏的口腔护理产品或药品 |
CN111249291A (zh) * | 2020-03-19 | 2020-06-09 | 广西馨海药业科技有限公司 | 白头翁皂苷b4在制备治疗/预防细菌性肺炎药物的用途 |
-
2021
- 2021-06-12 CN CN202110657506.XA patent/CN113318002B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108451964A (zh) * | 2018-07-02 | 2018-08-28 | 苏州大学 | 白头翁皂苷b5在制备抗炎症性肠病药物中的应用 |
CN111249289A (zh) * | 2020-02-14 | 2020-06-09 | 广西英路维特药物有限公司 | 一种消炎和/或抗过敏的口腔护理产品或药品 |
CN111249291A (zh) * | 2020-03-19 | 2020-06-09 | 广西馨海药业科技有限公司 | 白头翁皂苷b4在制备治疗/预防细菌性肺炎药物的用途 |
Non-Patent Citations (5)
Title |
---|
《白头翁总皂苷提取物的基本理化性质考察》;管咏梅等;《白头翁总皂苷提取物的基本理化性质考察"》;中国实验方剂学杂志;第1-4页 * |
东华医疗.《https://mp.weixin.qq.com/s/40pNaGM7UNKp0rGjgIz-cw》.《神秘巨星-朝鲜白头翁》.微信公众号,2020, * |
中药蒙药普查办公室.《https://mp.weixin.qq.com/s/EDRDjkN1M77OHOTQ-Sf5vw》.《行走的植物药志,治痢"能手"~白头翁》.微信公众号,2020, * |
刘卫.《经皮给药纳米技术》.中国医药科学技术出版社 ,2020,67-68. * |
徐昌敏.《临床皮肤病诊疗新进展》.2014, * |
Also Published As
Publication number | Publication date |
---|---|
CN113318002A (zh) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113318002B (zh) | 消炎祛痘组合物及化妆品 | |
Zhang et al. | Astaxanthin offers neuroprotection and reduces neuroinflammation in experimental subarachnoid hemorrhage | |
CN106727147A (zh) | 草本洋参皮肤美容改善药物及化妆品应用和制备 | |
CN108904376A (zh) | 一种具有控油祛痘功效的化妆品用中药复方发酵液及其制备与应用 | |
Xu et al. | Effects of aqueous extracts of Ecliptae herba, Polygoni multiflori radix praeparata and Rehmanniae radix praeparata on melanogenesis and the migration of human melanocytes | |
CN113855718A (zh) | 青蒿提取物及其应用 | |
CN101890030A (zh) | 抗菌、抗病毒、抗氧化及抗色素沉积的组合物 | |
TW201934740A (zh) | 橘皮發酵物及其製備方法與應用 | |
Han et al. | [Retracted] Immunomodulatory Effect of Lycium barbarum Polysaccharides against Liver Fibrosis Based on the Intelligent Medical Internet of Things | |
CN109276504A (zh) | 一种柒香嫩容散发酵原浆化妆品及其制备方法与应用 | |
CN101322746B (zh) | 二次发酵法天然药物制剂、制备方法及用途 | |
CN103372076B (zh) | 治疗由痤疮丙酸杆菌引起的疾病的药物、及地榆和/或地榆提取物的应用 | |
KR20200058849A (ko) | 면역활성이 높은 락토바실러스 사케이 probio-65 사균 또는 락토바실러스 사케이 probio-65 추출물을 포함하는 아토피성 피부염 증상 저감 또는 치료용 조성물 | |
CN113171316B (zh) | 一种修复、缓解皮肤刺激化妆品及制备方法 | |
CN108354891A (zh) | 一种舒缓乳霜及其制备方法 | |
CN105055248B (zh) | 远志总皂苷在制备皮肤抗衰老日化产品中的应用及其制备的抗衰老日化产品 | |
CN114848791A (zh) | 用于预防、改善皮肤炎症的小分子燕窝肽的应用 | |
Song et al. | Lactobacillus plantarum fermented Laminaria japonica alleviates UVB-induced epidermal photoinflammation via the Keap-1/Nrf2 pathway | |
KR20170027421A (ko) | 복합 한약재 추출물 함유 기능성 화장료 조성물 및 그 제조 방법 | |
CN115837060B (zh) | 小米发酵物在制备防治湿疹的药物中的应用及乳膏 | |
CN115177562B (zh) | 具有抗敏舒缓功效的植物复合发酵原浆的制备方法和应用 | |
CN115998793B (zh) | 一种提高机体学习记忆能力的保元汤及制备方法 | |
CN108114083A (zh) | 一种防治肝损伤的中药组合物 | |
KR102209969B1 (ko) | 절패모의 추출물을 함유하는 아토피 예방 또는 치료용 조성물 | |
Tjampakasari et al. | Description of Methicilin-Sensitive Staphylococcus aureus (MSSA) and Methicilin-Resistant Staphylococcus aureus (MRSA) against Fluoroquinolone and Vancomycin Group Antibiotics in Jakarta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |